{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:15:24Z","timestamp":1793330124889,"version":"4.5.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>Background\/Objectives:<\/jats:title>\n            <jats:p>The outcome of Burkitt lymphoma has improved by over 90%. In this study, demographic characteristics and outcomes of 57 patients with Burkitt lymphoma treated with FAB LMB 96 regimen are presented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>Standard intensity arms were selected for all risk groups. Clinical characteristics, response to treatment, and outcome were evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The median age of 48 boys and 9 girls was 8.2 years. There were 2 (3%), 41 (72%), and 14 (25%) patients in the low, intermediate, and high-risk groups, respectively. Patients were followed-up for a median of 50 months. The 5-year overall survival and event-free survival rates for the study group were 90.8% and 87.4%, respectively. Two patients in the low-risk group are still alive without evidence of disease for 17 and 57 months. The 5-year overall survival rates were 95% and 78% for intermediate and high-risk patients, and the 5-year event-free survival rates were 93% and 62%, respectively. At the end of induction, 58% of patients had complete response, and 42% (n=24) had residual tumors. A total of 16 of 24 patient biopsies showed no viable tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our results confirm the previously published survival results of FAB LMB 96. The regimen is an effective regimen for mature B-cell non-Hodgkin lymphoma without radiotherapy or surgery even in central nervous system\u2013positive patients. The most important prognostic factor is the complete response after induction chemotherapy. However, residual tumor at the end of consolidation might not always be a sign for unresponsive tumor. Tumoral residue should be radiologically well evaluated and biopsied if possible for viability before intensifying treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000001270","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T19:44:48Z","timestamp":1532720688000},"page":"e7-e11","source":"Crossref","is-referenced-by-count":6,"title":["FAB LMB 96 Regimen for Newly Diagnosed Burkitt Lymphoma in Children: Single-center Experience"],"prefix":"10.1097","volume":"41","author":[{"given":"Burca","family":"Aydin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Akyuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neslihan","family":"Kalkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilgun","family":"Kurucu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Varan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgehan","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tezer","family":"Kutluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ctrv.2010.02.003","article-title":"Epidemiology of childhood cancer","volume":"36","author":"Kaatsch","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin\u2019s lymphoma: results of the FAB\/LMB 96 international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br J Haematol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MPH.0b013e31819a5d58","article-title":"Burkitt lymphoma in children: the Israeli experience","volume":"31","author":"Eldar","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/10428194.2010.537794","article-title":"Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood","volume":"52","author":"Fujita","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R7-20230918","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-M\u00fcnster Group Trial NHL-BFM 90","volume":"94","author":"Reiter","year":"1999","journal-title":"Blood"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"R9-20230918","first-page":"346","article-title":"LMB chemotherapy for mature B-cell neoplasms in children: a single-center experience","volume":"57","author":"Osumi","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1081\/CNV-120002487","article-title":"Clinical characteristics and treatment results of LMB\/LMT regimen in children with non-Hodgkin\u2019s lymphoma","volume":"20","author":"Kutluk","year":"2002","journal-title":"Cancer Invest"},{"key":"R11-20230918","first-page":"81","article-title":"Burkitt\u2019s lymphoma in Turkish Children: a retrospective analysis of 104 cases","volume":"23","author":"Kutluk","year":"1993","journal-title":"Turk J Cancer"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mpo.2950210108","article-title":"Burkitt\u2019s lymphoma between African and American types in Turkish children: clinical, viral (EBV), and molecular studies","volume":"21","author":"Cavdar","year":"1993","journal-title":"Med Pediatr Oncol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.2910230104","article-title":"Burkitt\u2019s lymphoma in Iraq. Clinical and pathological study of forty-seven patients","volume":"23","author":"Al-Attar","year":"1979","journal-title":"Int J Cancer"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MPH.0b013e31829d4900","article-title":"Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study","volume":"36","author":"Samochatova","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/pbc.21452","article-title":"Treatment of B-cell lymphoma with LMB modified protocols in Africa\u2014report of the French-African Pediatric Oncology Group (GFAOP)","volume":"50","author":"Harif","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"5","author":"Griffin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"issue":"15_suppl","key":"R19-20230918","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","article-title":"Results of the randomized intergroup trial inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen","volume":"34","author":"Minard-Colin","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201901000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:41:16Z","timestamp":1695012076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201901000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001270","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}